
|Articles|October 1, 2002
Tazarotene indications may soon expand
Los Angeles - Already approved for the treatment of acne, tazarotene (Tazorac) is being investigated for the treatment of facial photodamage and clogged pores. The FDA is expected to grant regulatory approval for tazarotene to treat photodamaged facial skin within a few months.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
3
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
4
Introducing Dermatology Times NP/PA Connect
5











